Leerink Partnrs Boosts Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Disc Medicine in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($5.33) per share for the year, up from their previous forecast of ($5.75). The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share. Leerink Partnrs also issued estimates for Disc Medicine's FY2026 earnings at ($7.69) EPS, FY2027 earnings at ($8.80) EPS, FY2028 earnings at ($7.74) EPS and FY2029 earnings at ($6.31) EPS.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15.

A number of other research analysts have also commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Scotiabank upped their price target on shares of Disc Medicine from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research note on Wednesday, January 22nd. Raymond James upgraded shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. HC Wainwright reissued a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 target price on the stock in a report on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $88.90.

Disc Medicine Stock Up 0.9 %

Shares of Disc Medicine stock traded up $0.46 on Monday, hitting $54.10. The stock had a trading volume of 156,314 shares, compared to its average volume of 417,325. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -13.59 and a beta of 0.73. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60. The business's 50 day moving average is $60.37 and its two-hundred day moving average is $54.63.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors have recently added to or reduced their stakes in IRON. FMR LLC grew its stake in shares of Disc Medicine by 358.7% during the fourth quarter. FMR LLC now owns 1,866,248 shares of the company's stock worth $118,320,000 after buying an additional 1,459,434 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Disc Medicine by 68.2% during the 3rd quarter. Janus Henderson Group PLC now owns 749,827 shares of the company's stock valued at $36,828,000 after acquiring an additional 303,954 shares in the last quarter. State Street Corp grew its position in Disc Medicine by 39.7% during the 3rd quarter. State Street Corp now owns 827,910 shares of the company's stock worth $40,683,000 after acquiring an additional 235,115 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Disc Medicine in the 4th quarter worth about $5,579,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Disc Medicine during the fourth quarter valued at about $5,479,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Disc Medicine

In related news, CEO John D. Quisel sold 12,791 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $66.01, for a total value of $844,333.91. Following the sale, the chief executive officer now directly owns 72,065 shares of the company's stock, valued at $4,757,010.65. This trade represents a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $55.54, for a total value of $416,550.00. Following the completion of the transaction, the insider now owns 14,035 shares in the company, valued at approximately $779,503.90. This represents a 34.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,921 shares of company stock valued at $5,389,978 over the last three months. 4.24% of the stock is owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.